|

Impact of Genetic Polymorphisms And DASH Diet On Weight Loss Progression In Climacteric Women With Metabolic Syndrome

RECRUITINGN/ASponsored by Nutrindo Ideais Research Center
Actively Recruiting
PhaseN/A
SponsorNutrindo Ideais Research Center
Started2025-04-01
Est. completion2025-08-01
Eligibility
Age40 Years – 60 Years
SexFEMALE
Healthy vol.Accepted

Summary

Metabolic syndrome is a multifactorial inflammatory condition that is very prevalent in overweight women with type 2 diabetes. However, there seems to be great benefit in changing lifestyle and dietary patterns in the treatment of this condition. Currently, few studies have shown the effect of a Dietary Approach to Stop Hypertension (DASH) diet in postmenopausal women with metabolic syndrome and the influence of genetic polymorphisms of the fat mass and obesity-associated protein (FTO) and beta-2 adrenergic receptor (ADRB2) genes on inflammatory markers and improvement of laboratory indicators in these patients. This study aims to analyze the interaction of polymorphisms in the ADRB2 and FTO genes and the DASH diet on anthropometric indicators and laboratory tests in patients with metabolic syndrome in the city of Rio de Janeiro. For this purpose, laboratory tests and anthropometric data will be collected in a prospective study with women aged between 40 and 60 years.

Eligibility

Age: 40 Years – 60 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* The study population will consist of menopausal women aged between 40 to 60 years old
* Obese (BMI \> 30) with a diagnosis of MS.

The inclusion criteria are the presence of at least 3 of the 5 criteria\* for MS, which include:

* Abnormal waist circumference values (≥89 cm in women)
* SBP ≥120 mm Hg and DBP ≥80 mm Hg) or diagnosis of hypertension
* Fasting blood glucose equal to or greater than 100 mg/dL or diagnosis of DM2
* HDL-c less than 50 mg/dL in women
* Triglycerides ≥150 mg/dL.

Exclusion Criteria:

* Patients with a BMI \<25 kg/m2

The following chronic diseases will not be eligible:

* Active cancer
* Active tuberculosis
* Psychiatric illnesses
* Multiple sclerosis
* Severe nephropathy
* Advanced stages of Paget's disease.

These chronic conditions could interfere with the results of this study, especially adherence to diet and weight loss. Patients who do not complete all stages of the study, who are not adhering to the intervention or who present any complication that interferes with the results of the study will be excluded from the study.

Conditions5

Genetic PolymorphismsMetabolic SyndromeNutritionObesityWeight Loss

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.